NEWS

Philips announces first patient enrolled in the WE-TRUST global multicen...

Amsterdam, the Netherlands –  Royal Philips  (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the first patient has been enrolled in the WE-TRUST study at Vall d’Hebron University Hospital, Barcelona, Spain, marking the official start of this major multicenter randomized controlled trial to assess if the  Direct to Angio Suite  workflow can improve outcomes for early time-window stroke patients (less than six hours after stroke onset).

Philips accelerates stroke diagnosis and treatment with expanded integra...

Amsterdam, the Netherlands –  Royal Philips  (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a strategic partnership agreement with  NICO.LAB , a MedTech stroke care company. Together with the recently expanded stroke capabilities of Philips Image Guided Therapy System – Azurion – this new partnership significantly advances Philips’ commitment to improving outcomes for people who suffer a stroke. Philips is connecting information, technologies and people across the stroke care pathway, enabling care teams to work quickly and act decisively - a key factor in providing the best patient treatment.

Download the LINNC INR Trials book!

Transradial MCA stenting

Sensome receives FDA "Breakthrough device designation" for its AI-powere...

Paris, France, June 21st, 2021, – Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today that it has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for its Clotild® Smart Guidewire System designed to improve the treatment of ischemic stroke patients.

MT in a patient with a history of giant fusiform aneurysm

Vesalio Secures Class A Funding

Nashville, TN, June 2, 2021 Vesalio announces it has successfully secured a Class A financing round. The proceeds will be utilized to support the ongoing US IDE stroke study, establish US infrastructure, expand its innovative product portfolio, and scale international business. This round, led by Solas BioVentures, included participation from both new and existing investors.

Endovascular bail-out after massive rupture

A Case of Ruptured Brain Stem AVM Causing vessel Perforation

Vesalio Initiates FDA IDE Stroke Study

Nashville, TN, May 11, 2021 Vesalio announces another key milestone to support entry into the US neurovascular thrombectomy market. Enrollment has commenced in the Vesalio CLEAR(1) acute ischemic stroke FDA IDE clinical trial utilizing the NeVaTM thrombectomy technology platform. With twenty participating stroke treatment centers, enrollment is expected to be completed in early 2022.